Neil Gittoes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil Gittoes has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Jo Leonardi-Bee
Centre for Evidence Based Healthcare, University of Nottingham, Nottingham, UK
4 shared publications - Opinder Sahota
Nottingham University Hospitals NHS Trust
4 shared publications - Simon Bishop
Nottingham University Business School, University of Nottingham, Nottingham, UK
4 shared publications - Tessa Langley
Nottingham Centre for Public Health and Epidemiology, University of Nottingham, Nottingham, UK
4 shared publications - Zoe Paskins
Centre for Musculoskeletal Health Research, School of Medicine Staffordshire England Keele University
4 shared publications - Anastasios Bastounis
School of Medicine and Population Health, University of Sheffield, Sheffield, UK
3 shared publications
Latest Publications
- 10 July 2026
- Published by Wiley in Clinical Endocrinology
- Vol. 105 (4) , 380-385
Referral to Definitive Surgical Treatment in Cushing's Syndrome – An Odyssey That Requires Attention
Objective: Cushing's syndrome (CS) requires prompt recognition and referral to explore definitive intervention. Delays can lead to increased mortality and death. This service evaluation aimed to distinguish time from initial referral to definitive surgical management in CS. Context: Clinical standards for appropriate timelines for referral are undefined. Design: A retrospective service evaluation across five specialised endocrine surgical centres reviewing the timeline from initial referral to definitive surgical treatment. Patients: All adult patients diagnosed with CS who underwent definitive surgery between January 2018 and December 2019. Measurements: Data were collected on initial referrer, time to first clinical review, tests performed within non‐surgical endocrinology centres, timing of referral to specialised endocrine surgical centre, clinical review (if applicable), multi‐disciplinary meeting and definitive surgery. Results: 71 patients received definitive surgical treatment for CS (37 pituitary CS and 34 adrenal CS). Median time from initial primary care referral to a specialised endocrine surgical centre was quicker if referred directly (56 days) than if initially referred to a non‐surgical endocrinology hospital (159 days). The overall median time from all initial referrals to definitive surgical treatment was 211 days for pituitary CS and 253 days for adrenal CS. Patients referred directly to the specialised endocrine surgical centre had surgery in a median of 196 days (187 days and 252 days for pituitary and adrenal CS respectively) compared with 253 days in patients that were referred via a non‐surgical endocrinology centre (249 days and 346 days for pituitary and adrenal CS respectively). Conclusion: There were delays from initial referral to definitive surgical treatment of CS. Clearer, clinically focussed pathways and (inter)national standards on early management of Cushing's syndrome should be considered to more address unwarranted delays in treating Cushing's syndrome.
- 10 July 2026
- Published by Wiley in Clinical Endocrinology
- Vol. 105 (4) , 380-385
Referral to Definitive Surgical Treatment in Cushing's Syndrome – An Odyssey That Requires Attention
Objective: Cushing's syndrome (CS) requires prompt recognition and referral to explore definitive intervention. Delays can lead to increased mortality and death. This service evaluation aimed to distinguish time from initial referral to definitive surgical management in CS. Context: Clinical standards for appropriate timelines for referral are undefined. Design: A retrospective service evaluation across five specialised endocrine surgical centres reviewing the timeline from initial referral to definitive surgical treatment. Patients: All adult patients diagnosed with CS who underwent definitive surgery between January 2018 and December 2019. Measurements: Data were collected on initial referrer, time to first clinical review, tests performed within non‐surgical endocrinology centres, timing of referral to specialised endocrine surgical centre, clinical review (if applicable), multi‐disciplinary meeting and definitive surgery. Results: 71 patients received definitive surgical treatment for CS (37 pituitary CS and 34 adrenal CS). Median time from initial primary care referral to a specialised endocrine surgical centre was quicker if referred directly (56 days) than if initially referred to a non‐surgical endocrinology hospital (159 days). The overall median time from all initial referrals to definitive surgical treatment was 211 days for pituitary CS and 253 days for adrenal CS. Patients referred directly to the specialised endocrine surgical centre had surgery in a median of 196 days (187 days and 252 days for pituitary and adrenal CS respectively) compared with 253 days in patients that were referred via a non‐surgical endocrinology centre (249 days and 346 days for pituitary and adrenal CS respectively). Conclusion: There were delays from initial referral to definitive surgical treatment of CS. Clearer, clinically focussed pathways and (inter)national standards on early management of Cushing's syndrome should be considered to more address unwarranted delays in treating Cushing's syndrome.
- Open Access
- 6 April 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 299 (6) , 650-669
Individualized management of primary hyperparathyroidism
Primary hyperparathyroidism (PHPT) is a common endocrine disease that typically presents in peri‐ and postmenopausal women. PHPT is due to a single parathyroid adenoma in most cases, which leads to stable hypercalcemia over years. Nowadays, the diagnosis is often coincidental, reached by chance in subjects without specific symptoms—asymptomatic PHPT. However, the patients might have subtle disease‐related manifestations. Management standards have been reviewed through international workshops over more than three decades, leading to absolute and relative indications for parathyroidectomy (PTX), the only curative treatment. The alternative to PTX is observation without intervention in asymptomatic patients without organ manifestations and only mildly elevated calcium levels (mild PHPT). On the basis of recent literature, our aim is to challenge current recommendations for managing PHPT with focus on mild asymptomatic disease, integrating informed patient preferences. Considering the changing patient demography with increasing life expectancy, more sensitive visualization procedures, improved surgical techniques, and new data on PHPT‐related morbidity, we test some of the established indications for PTX, particularly age as an isolated criterion, and the validity of a circulating calcium “threshold” for considering PTX. Additionally, bone mineral density (BMD) decreases for at least a decade with observation in contrast to PTX, where BMD normalizes after surgery and remains stable in the axial compartments for years. Therefore, skeletal‐related thresholds for PTX also deserve review. In conclusion, we suggest integrating more clinical outcomes and wider perspectives in decision‐making for the management of mild PHPT, taking patient preferences into consideration, and focusing on informed and shared decision‐making.
- 6 April 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 299 (6) , 650-669
Open AccessIndividualized management of primary hyperparathyroidism
Primary hyperparathyroidism (PHPT) is a common endocrine disease that typically presents in peri‐ and postmenopausal women. PHPT is due to a single parathyroid adenoma in most cases, which leads to stable hypercalcemia over years. Nowadays, the diagnosis is often coincidental, reached by chance in subjects without specific symptoms—asymptomatic PHPT. However, the patients might have subtle disease‐related manifestations. Management standards have been reviewed through international workshops over more than three decades, leading to absolute and relative indications for parathyroidectomy (PTX), the only curative treatment. The alternative to PTX is observation without intervention in asymptomatic patients without organ manifestations and only mildly elevated calcium levels (mild PHPT). On the basis of recent literature, our aim is to challenge current recommendations for managing PHPT with focus on mild asymptomatic disease, integrating informed patient preferences. Considering the changing patient demography with increasing life expectancy, more sensitive visualization procedures, improved surgical techniques, and new data on PHPT‐related morbidity, we test some of the established indications for PTX, particularly age as an isolated criterion, and the validity of a circulating calcium “threshold” for considering PTX. Additionally, bone mineral density (BMD) decreases for at least a decade with observation in contrast to PTX, where BMD normalizes after surgery and remains stable in the axial compartments for years. Therefore, skeletal‐related thresholds for PTX also deserve review. In conclusion, we suggest integrating more clinical outcomes and wider perspectives in decision‐making for the management of mild PHPT, taking patient preferences into consideration, and focusing on informed and shared decision‐making.
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii23-ii34
EndoCompass project: research roadmap for calcium and bone endocrinology
Background: Endocrine science remains underrepresented in European Union research programmes despite the fundamental role of hormone health in human well-being. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology—aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in bone and calcium endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results: Research priorities encompass primary hyperparathyroidism, chronic hypoparathyroidism, and rare calcium–phosphate disorders. Key areas include bone as endocrine organ, bone mass acquisition, secondary osteoporosis, and skeletal dysplasias. Special emphasis is placed on cellular senescence, sex-specific differences in disease manifestation, and development of novel diagnostic tools for bone quality assessment. Conclusions: This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into metabolic bone disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.
- 17 October 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (Supplement) , ii23-ii34
Open AccessEndoCompass project: research roadmap for calcium and bone endocrinology
Background: Endocrine science remains underrepresented in European Union research programmes despite the fundamental role of hormone health in human well-being. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology—aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in bone and calcium endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results: Research priorities encompass primary hyperparathyroidism, chronic hypoparathyroidism, and rare calcium–phosphate disorders. Key areas include bone as endocrine organ, bone mass acquisition, secondary osteoporosis, and skeletal dysplasias. Special emphasis is placed on cellular senescence, sex-specific differences in disease manifestation, and development of novel diagnostic tools for bone quality assessment. Conclusions: This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into metabolic bone disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.
- Open Access
- 1 April 2024
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 28 (21) , 1-169
Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study
Background: Bisphosphonates are a class of medication commonly used to treat osteoporosis. Alendronate is recommended as the first-line treatment; however, long-term adherence (both treatment compliance and persistence) is poor. Alternative bisphosphonates are available, which can be given intravenously and have been shown to improve long-term adherence. However, the most clinically effective and cost-effective alternative bisphosphonate regimen remains unclear. What is the most cost-effective bisphosphonate in clinical trials may not be the most cost-effective or acceptable to patients in everyday clinical practice. Objectives: 1. Explore patient, clinician and stakeholder views, experiences and preferences of alendronate compared to alternative bisphosphonates. 2. Update and refine the 2016 systematic review and cost-effectiveness analysis of bisphosphonates, and estimate the value of further research into their benefits. 3. Undertake stakeholder/consensus engagement to identify important research questions and further rank research priorities. Methods: The study was conducted in two stages, stages 1A and 1B in parallel, followed by stage 2: center dot Stage 1A - we elicited patient and healthcare experiences to understand their preferences of bisphosphonates for the treatment of osteoporosis. This was undertaken by performing a systematic review and framework synthesis of qualitative studies, followed by semistructured qualitative interviews with participants. center dot Stage 1B - we updated and expanded the existing Health Technology Assessment systematic review and clinical and cost-effectiveness model, incorporating a more comprehensive review of treatment efficacy, safety, side effects, compliance and long-term persistence. center dot Stage 2 - we identified and ranked further research questions that need to be answered about the effectiveness and acceptability of bisphosphonates. Results: Patients and healthcare professionals identified a number of challenges in adhering to bisphosphonate medication, balancing the potential for long-term risk reduction against the work involved in adhering to oral alendronate. Intravenous zoledronate treatment was generally more acceptable, with such regimens perceived to be more straightforward to engage in, although a portion of patients taking alendronate were satisfied with their current treatment. Intravenous zoledronate was found to be the most effective, with higher adherence rates compared to the other bisphosphonates, for reducing the risk of fragility fracture. However, oral bisphosphonates are more cost-effective than intravenous zoledronate due to the high cost of zoledronate administration in hospital. The importance of including patients and healthcare professionals when setting research priorities is recognised. Important areas for research were related to patient factors influencing treatment selection and effectiveness, how to optimise long-term care and the cost-effectiveness of delivering zoledronate in an alternative, non-hospital setting. Conclusions: Intravenous zoledronate treatment was generally more acceptable to patients and found to be the most effective bisphosphonate and with greater adherence; however, the cost-effectiveness relative to oral alendronate is limited by its higher zoledronate hospital administration costs. Future work: Further research is needed to support people to make decisions influencing treatment selection, effectiveness and optimal long-term care, together with the clinical and cost-effectiveness of intravenous zoledronate administered in a non-hospital (community) setting. Limitations: Lack of clarity and limitations in the many studies included in the systematic review may have under-interpreted some of the findings relating to effects of bisphosphonates. Trial registration: This trial is registered as ISRCTN10491361
- 1 April 2024
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 28 (21) , 1-169
Open AccessBisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study
Background: Bisphosphonates are a class of medication commonly used to treat osteoporosis. Alendronate is recommended as the first-line treatment; however, long-term adherence (both treatment compliance and persistence) is poor. Alternative bisphosphonates are available, which can be given intravenously and have been shown to improve long-term adherence. However, the most clinically effective and cost-effective alternative bisphosphonate regimen remains unclear. What is the most cost-effective bisphosphonate in clinical trials may not be the most cost-effective or acceptable to patients in everyday clinical practice. Objectives: 1. Explore patient, clinician and stakeholder views, experiences and preferences of alendronate compared to alternative bisphosphonates. 2. Update and refine the 2016 systematic review and cost-effectiveness analysis of bisphosphonates, and estimate the value of further research into their benefits. 3. Undertake stakeholder/consensus engagement to identify important research questions and further rank research priorities. Methods: The study was conducted in two stages, stages 1A and 1B in parallel, followed by stage 2: center dot Stage 1A - we elicited patient and healthcare experiences to understand their preferences of bisphosphonates for the treatment of osteoporosis. This was undertaken by performing a systematic review and framework synthesis of qualitative studies, followed by semistructured qualitative interviews with participants. center dot Stage 1B - we updated and expanded the existing Health Technology Assessment systematic review and clinical and cost-effectiveness model, incorporating a more comprehensive review of treatment efficacy, safety, side effects, compliance and long-term persistence. center dot Stage 2 - we identified and ranked further research questions that need to be answered about the effectiveness and acceptability of bisphosphonates. Results: Patients and healthcare professionals identified a number of challenges in adhering to bisphosphonate medication, balancing the potential for long-term risk reduction against the work involved in adhering to oral alendronate. Intravenous zoledronate treatment was generally more acceptable, with such regimens perceived to be more straightforward to engage in, although a portion of patients taking alendronate were satisfied with their current treatment. Intravenous zoledronate was found to be the most effective, with higher adherence rates compared to the other bisphosphonates, for reducing the risk of fragility fracture. However, oral bisphosphonates are more cost-effective than intravenous zoledronate due to the high cost of zoledronate administration in hospital. The importance of including patients and healthcare professionals when setting research priorities is recognised. Important areas for research were related to patient factors influencing treatment selection and effectiveness, how to optimise long-term care and the cost-effectiveness of delivering zoledronate in an alternative, non-hospital setting. Conclusions: Intravenous zoledronate treatment was generally more acceptable to patients and found to be the most effective bisphosphonate and with greater adherence; however, the cost-effectiveness relative to oral alendronate is limited by its higher zoledronate hospital administration costs. Future work: Further research is needed to support people to make decisions influencing treatment selection, effectiveness and optimal long-term care, together with the clinical and cost-effectiveness of intravenous zoledronate administered in a non-hospital (community) setting. Limitations: Lack of clarity and limitations in the many studies included in the systematic review may have under-interpreted some of the findings relating to effects of bisphosphonates. Trial registration: This trial is registered as ISRCTN10491361
- Open Access
- 29 September 2023
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 24 (1) , 1-10
Clinicians’ views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study
Background: Bisphosphonate medications, including alendronate, ibandronate and risedronate administered orally and zoledronate, administered intravenously, are commonly prescribed for the treatment of osteoporosis based on evidence that, correctly taken, bisphosphonates can improve bone strength and lead to a reduction in the risk of fragility fractures. However, it is currently unclear how decisions to select between bisphosphonate regimens, including intravenous regimen, are made in practice and how clinicians support patients with different treatments. Methods: This was an interpretivist qualitative study. 23 semi-structured telephone interviews were conducted with a sample of general practitioners (GPs), secondary care clinicians, specialist experts as well as those providing and leading novel treatments including participants from a community intravenous (IV) zoledronate service. Data analysis was undertaken through a process of iterative categorisation. Results: The results report clinicians varying experiences of making treatment choices, as well as wider aspects of osteoporosis care. Secondary care and specialist clinicians conveyed some confidence in making treatment choices including on selecting IV treatment. This was aided by access to diagnostic testing and medication expertise. In contrast GPs reported a number of challenges in prescribing bisphosphonate medications for osteoporosis and uncertainty about treatment choice. Results also highlight how administering IV zoledronate was seen as an opportunity to engage in broader care practices. Conclusion: Approaches to making treatment decisions and supporting patients when prescribing bisphosphonates for osteoporosis vary in practice. This study points to the need to co-ordinate osteoporosis treatment and care across different care providers.
- 29 September 2023
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 24 (1) , 1-10
Open AccessClinicians’ views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study
Background: Bisphosphonate medications, including alendronate, ibandronate and risedronate administered orally and zoledronate, administered intravenously, are commonly prescribed for the treatment of osteoporosis based on evidence that, correctly taken, bisphosphonates can improve bone strength and lead to a reduction in the risk of fragility fractures. However, it is currently unclear how decisions to select between bisphosphonate regimens, including intravenous regimen, are made in practice and how clinicians support patients with different treatments. Methods: This was an interpretivist qualitative study. 23 semi-structured telephone interviews were conducted with a sample of general practitioners (GPs), secondary care clinicians, specialist experts as well as those providing and leading novel treatments including participants from a community intravenous (IV) zoledronate service. Data analysis was undertaken through a process of iterative categorisation. Results: The results report clinicians varying experiences of making treatment choices, as well as wider aspects of osteoporosis care. Secondary care and specialist clinicians conveyed some confidence in making treatment choices including on selecting IV treatment. This was aided by access to diagnostic testing and medication expertise. In contrast GPs reported a number of challenges in prescribing bisphosphonate medications for osteoporosis and uncertainty about treatment choice. Results also highlight how administering IV zoledronate was seen as an opportunity to engage in broader care practices. Conclusion: Approaches to making treatment decisions and supporting patients when prescribing bisphosphonates for osteoporosis vary in practice. This study points to the need to co-ordinate osteoporosis treatment and care across different care providers.
- 9 June 2023
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (10) , 1711-1718
Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise
Purpose Worldwide, many people who would benefit from osteoporosis drugs are not offered or receiving them, resulting in an osteoporosis care gap. Adherence with bisphosphonates is particularly low. This study aimed to identify stakeholder research priorities relating to bisphosphonate treatment regimens for prevention of osteoporotic fractures. Methods A three-step approach based on the James Lind Alliance methodology for identification and prioritisation of research questions was used. Research uncertainties were gathered from a large programme of related research studies about bisphosphonate regimens and from recent published international clinical guidelines. Clinical and public stakeholders refined the list of uncertainties into research questions. The third step prioritised the questions using a modified nominal group technique. Results In total, 34 draft uncertainties were finalised into 33 research questions by stakeholders. The top 10 includes questions relating to which people should be offered intravenous bisphosphonates first line (1); optimal duration of treatment (2); the role of bone turnover markers in treatment breaks (3); support patient need for medicine optimisation (4); support primary care practitioner need regarding bisphosphonates (5); comparing zoledronate given in community vs hospital settings (6); ensuring quality standards are met (7); the long-term model of care (8); best bisphosphonate for people aged under 50 (9); and supporting patient decision-making about bisphosphonates (10). Conclusion This study reports, for the first time, topics of importance to stakeholders in the research of bisphosphonate osteoporosis treatment regimens. These findings have implications for research into implementation to address the care gap and education of healthcare professionals. Summary Using James Lind Alliance methodology, this study reports prioritised topics of importance to stakeholders in the research of bisphosphonate treatment in osteoporosis. The priorities address how to better implement guidelines to address the care gap, understanding patient factors influencing treatment selection and effectiveness, and how to optimise long-term care.
- 9 June 2023
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (10) , 1711-1718
Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise
Purpose Worldwide, many people who would benefit from osteoporosis drugs are not offered or receiving them, resulting in an osteoporosis care gap. Adherence with bisphosphonates is particularly low. This study aimed to identify stakeholder research priorities relating to bisphosphonate treatment regimens for prevention of osteoporotic fractures. Methods A three-step approach based on the James Lind Alliance methodology for identification and prioritisation of research questions was used. Research uncertainties were gathered from a large programme of related research studies about bisphosphonate regimens and from recent published international clinical guidelines. Clinical and public stakeholders refined the list of uncertainties into research questions. The third step prioritised the questions using a modified nominal group technique. Results In total, 34 draft uncertainties were finalised into 33 research questions by stakeholders. The top 10 includes questions relating to which people should be offered intravenous bisphosphonates first line (1); optimal duration of treatment (2); the role of bone turnover markers in treatment breaks (3); support patient need for medicine optimisation (4); support primary care practitioner need regarding bisphosphonates (5); comparing zoledronate given in community vs hospital settings (6); ensuring quality standards are met (7); the long-term model of care (8); best bisphosphonate for people aged under 50 (9); and supporting patient decision-making about bisphosphonates (10). Conclusion This study reports, for the first time, topics of importance to stakeholders in the research of bisphosphonate osteoporosis treatment regimens. These findings have implications for research into implementation to address the care gap and education of healthcare professionals. Summary Using James Lind Alliance methodology, this study reports prioritised topics of importance to stakeholders in the research of bisphosphonate treatment in osteoporosis. The priorities address how to better implement guidelines to address the care gap, understanding patient factors influencing treatment selection and effectiveness, and how to optimise long-term care.
- 7 May 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 81
Time from referral to definitive treatment in Cushing's syndrome
Rapid diagnosis and treatment of Cushing’s syndrome (CS) is essential for good outcomes. Current standards for appropriate timelines for referral are under review by NHSE. Data are required to substantiate standard setting. Knowledge of current referral pathways/processes are required to explore delays in accessing definitive surgical treatment. An audit of referral processes at Queen Elizabeth Hospital Birmingham was undertaken and further expanded to 4 additional tertiary centres in England. Data were collected on adult patients diagnosed with CS and referred for surgery at index hospitals between January 2018 and December 2019. Patients seen privately were excluded until seen in index hospital. Data were collected on demographics, initial referrer and referral pathway and dates of first clinic, subsequent referral to index hospital (if applicable), first index hospital clinic, MDT and definitive surgery. 72 patients were diagnosed with CS; 69 had definitive surgical treatment. 37 patients had pituitary CS, 34 adrenal CS, 1 had ectopic ACTH secretion. Demographics and referral pathways are outlined in table below. Results are given as median averages. Time from initial referral to secondary clinic (39.5 days in all patients, 45 days in pituitary and 35 days in adrenal patients) was shorter than those referred direct to index tertiary clinic (57 days in all-comers, 56 days in pituitary and 62 days in adrenal patients). However, total time from referral to tertiary clinic via secondary pathway was significantly longer (158.5 days in all, 140 days in pituitary and 171 in adrenal patients). The number of diagnostic tests performed in secondary care was 6 in each group. Time from referral to index hospital to MDT was 32, 61 and 22.5 days for all, pituitary and adrenal patients respectively. Time to definitive surgical treatment was 183, 178 and 180 days for all, pituitary and adrenal patients respectively. By mapping average timeline from referral to definitive surgical treatment in CS patients, we’ve highlighted areas of national and hospital-specific delays which can be improved for better patient outcomes. Both secondary and tertiary centres should organise more rapid reviews of patients with a potential diagnosis of CS and minimal investigation criteria should be set before secondary centres involve tertiary centres in management of CS patients. Table 1 All (n=72) Pituitary (n=31) Adrenal (n=34) Median age (years) 49 44 48 M:F ratio 17:55 8:29 8:26 Initial referrer GP 44(61.1%) 22(59.4%) 22(64.7%) Inpatient referral 25(34.7%) 13(35.1%) 12(35.3%) Initial clinic Secondary 44(61.1%) 20(54.1%) 24(70.6%) Index tertiary 22(30.6%) 14(37.8%) 7(20.6%)
- 7 May 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 81
Time from referral to definitive treatment in Cushing's syndrome
Rapid diagnosis and treatment of Cushing’s syndrome (CS) is essential for good outcomes. Current standards for appropriate timelines for referral are under review by NHSE. Data are required to substantiate standard setting. Knowledge of current referral pathways/processes are required to explore delays in accessing definitive surgical treatment. An audit of referral processes at Queen Elizabeth Hospital Birmingham was undertaken and further expanded to 4 additional tertiary centres in England. Data were collected on adult patients diagnosed with CS and referred for surgery at index hospitals between January 2018 and December 2019. Patients seen privately were excluded until seen in index hospital. Data were collected on demographics, initial referrer and referral pathway and dates of first clinic, subsequent referral to index hospital (if applicable), first index hospital clinic, MDT and definitive surgery. 72 patients were diagnosed with CS; 69 had definitive surgical treatment. 37 patients had pituitary CS, 34 adrenal CS, 1 had ectopic ACTH secretion. Demographics and referral pathways are outlined in table below. Results are given as median averages. Time from initial referral to secondary clinic (39.5 days in all patients, 45 days in pituitary and 35 days in adrenal patients) was shorter than those referred direct to index tertiary clinic (57 days in all-comers, 56 days in pituitary and 62 days in adrenal patients). However, total time from referral to tertiary clinic via secondary pathway was significantly longer (158.5 days in all, 140 days in pituitary and 171 in adrenal patients). The number of diagnostic tests performed in secondary care was 6 in each group. Time from referral to index hospital to MDT was 32, 61 and 22.5 days for all, pituitary and adrenal patients respectively. Time to definitive surgical treatment was 183, 178 and 180 days for all, pituitary and adrenal patients respectively. By mapping average timeline from referral to definitive surgical treatment in CS patients, we’ve highlighted areas of national and hospital-specific delays which can be improved for better patient outcomes. Both secondary and tertiary centres should organise more rapid reviews of patients with a potential diagnosis of CS and minimal investigation criteria should be set before secondary centres involve tertiary centres in management of CS patients. Table 1 All (n=72) Pituitary (n=31) Adrenal (n=34) Median age (years) 49 44 48 M:F ratio 17:55 8:29 8:26 Initial referrer GP 44(61.1%) 22(59.4%) 22(64.7%) Inpatient referral 25(34.7%) 13(35.1%) 12(35.3%) Initial clinic Secondary 44(61.1%) 20(54.1%) 24(70.6%) Index tertiary 22(30.6%) 14(37.8%) 7(20.6%)
- Top Cited PapersOpen Access
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (12) , 2568-2585
Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop
This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence-based recommendations. The HypoPT task forces included four teams with a total of 50 international experts including representatives from the sponsoring societies. A methodologist (GG) and his team supported the taskforces and conducted the systematic reviews. A formal process following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and the systematic reviews provided the structure for seven of the guideline recommendations. The task force used a less structured approach based on narrative reviews for 20 non-GRADEd recommendations. Clinicians may consider postsurgical HypoPT permanent if it persists for >12 months after surgery. To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total thyroidectomy (strong recommendation, moderate quality evidence). PTH > 10 pg/mL (1.05 pmol/L) virtually excludes long-term HypoPT. In individuals with nonsurgical HypoPT, genetic testing may be helpful in the presence of a positive family history of nonsurgical HypoPT, in the presence of syndromic features, or in individuals younger than 40 years. HypoPT can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataracts, seizures, cardiac arrhythmias, ischemic heart disease, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory indices. In patients with chronic HypoPT, the panel suggests conventional therapy with calcium and active vitamin D metabolites as first-line therapy (weak recommendation, low-quality evidence). When conventional therapy is deemed unsatisfactory, the panel considers the use of PTH. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (12) , 2568-2585
Top Cited PapersOpen AccessEvaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop
This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence-based recommendations. The HypoPT task forces included four teams with a total of 50 international experts including representatives from the sponsoring societies. A methodologist (GG) and his team supported the taskforces and conducted the systematic reviews. A formal process following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and the systematic reviews provided the structure for seven of the guideline recommendations. The task force used a less structured approach based on narrative reviews for 20 non-GRADEd recommendations. Clinicians may consider postsurgical HypoPT permanent if it persists for >12 months after surgery. To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total thyroidectomy (strong recommendation, moderate quality evidence). PTH > 10 pg/mL (1.05 pmol/L) virtually excludes long-term HypoPT. In individuals with nonsurgical HypoPT, genetic testing may be helpful in the presence of a positive family history of nonsurgical HypoPT, in the presence of syndromic features, or in individuals younger than 40 years. HypoPT can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataracts, seizures, cardiac arrhythmias, ischemic heart disease, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory indices. In patients with chronic HypoPT, the panel suggests conventional therapy with calcium and active vitamin D metabolites as first-line therapy (weak recommendation, low-quality evidence). When conventional therapy is deemed unsatisfactory, the panel considers the use of PTH. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- Open Access
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (11) , 2391-2403
Management of Primary Hyperparathyroidism
Since the last international guidelines were published in 2014 on the evaluation and management of primary hyperparathyroidism (PHPT), new information has become available with regard to evaluation, diagnosis, epidemiology, genetics, classical and nonclassical manifestations, surgical and nonsurgical approaches, and natural history. To provide the most current summary of these developments, an international group, consisting of over 50 experts in these various aspects of PHPT, was convened. This paper provides the results of the task force that was assigned to review the information on the management of PHPT. For this task force on the management of PHPT, two questions were the subject of systematic reviews using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology. The full report addressing surgical and nonsurgical management of PHPT, utilizing the GRADE methodology, is published separately in this series. In this report, we summarize the results of that methodological review and expand them to encompass a much larger body of new knowledge that did not specifically fit the criteria of the GRADE methodology. Together, both the systematic and narrative reviews of the literature, summarized in this paper, give the most complete information available to date. A panel of experts then considered the last set of international guidelines in light of the newer data and assessed the need for their revision. This report provides the evidentiary background to the guidelines report. In that report, evidence from all task forces is synthesized into a summary statement and revised guidelines for the evaluation and management of PHPT. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (11) , 2391-2403
Open AccessManagement of Primary Hyperparathyroidism
Since the last international guidelines were published in 2014 on the evaluation and management of primary hyperparathyroidism (PHPT), new information has become available with regard to evaluation, diagnosis, epidemiology, genetics, classical and nonclassical manifestations, surgical and nonsurgical approaches, and natural history. To provide the most current summary of these developments, an international group, consisting of over 50 experts in these various aspects of PHPT, was convened. This paper provides the results of the task force that was assigned to review the information on the management of PHPT. For this task force on the management of PHPT, two questions were the subject of systematic reviews using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology. The full report addressing surgical and nonsurgical management of PHPT, utilizing the GRADE methodology, is published separately in this series. In this report, we summarize the results of that methodological review and expand them to encompass a much larger body of new knowledge that did not specifically fit the criteria of the GRADE methodology. Together, both the systematic and narrative reviews of the literature, summarized in this paper, give the most complete information available to date. A panel of experts then considered the last set of international guidelines in light of the newer data and assessed the need for their revision. This report provides the evidentiary background to the guidelines report. In that report, evidence from all task forces is synthesized into a summary statement and revised guidelines for the evaluation and management of PHPT. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- Open Access
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (12) , 2602-2614
Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism
Chronic hypoparathyroidism is characterized by low serum calcium, increased serum phosphorus, and inappropriately low or decreased serum parathyroid hormone. This rare disorder is associated with a variety of complications. The prevalence, incidence, mortality, financial burden, and epidemiology of complications of this disorder are not well understood. This narrative review summarizes current information on the epidemiology and complications of chronic hypoparathyroidism. The reported prevalence of chronic hypoparathyroidism ranges from 6.4–37/100,000, and the incidence is reported to be 0.8–2.3/100,000/year. Mortality is not increased in studies from Denmark or South Korea but was increased in studies from Scotland and Sweden. The financial burden of this disorder is substantial because of increased health care resource utilization in two studies but not well quantitated. Recognized complications include hypercalciuria, nephrocalcinosis, kidney stones, and chronic kidney disease; low bone turnover and possibly upper extremity fractures; cardiac and vascular calcifications; basal ganglia calcifications, cataracts, infections, neuropsychiatric complications, and difficulties with pregnancy. This review concludes that chronic hypoparathyroidism is a rare disorder associated with significant morbidity that may not increase overall mortality but is associated with a substantial financial burden. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- 1 December 2020
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (12) , 2602-2614
Open AccessEpidemiology and Financial Burden of Adult Chronic Hypoparathyroidism
Chronic hypoparathyroidism is characterized by low serum calcium, increased serum phosphorus, and inappropriately low or decreased serum parathyroid hormone. This rare disorder is associated with a variety of complications. The prevalence, incidence, mortality, financial burden, and epidemiology of complications of this disorder are not well understood. This narrative review summarizes current information on the epidemiology and complications of chronic hypoparathyroidism. The reported prevalence of chronic hypoparathyroidism ranges from 6.4–37/100,000, and the incidence is reported to be 0.8–2.3/100,000/year. Mortality is not increased in studies from Denmark or South Korea but was increased in studies from Scotland and Sweden. The financial burden of this disorder is substantial because of increased health care resource utilization in two studies but not well quantitated. Recognized complications include hypercalciuria, nephrocalcinosis, kidney stones, and chronic kidney disease; low bone turnover and possibly upper extremity fractures; cardiac and vascular calcifications; basal ganglia calcifications, cataracts, infections, neuropsychiatric complications, and difficulties with pregnancy. This review concludes that chronic hypoparathyroidism is a rare disorder associated with significant morbidity that may not increase overall mortality but is associated with a substantial financial burden. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).